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Abstract
Background: Pegylated (PEG)-interferon (IFN)-alfa-2a plus ribavirin (RBV) therapy for 24 weeks is now a standard
treatment protocol for patients with hepatitis C virus (HCV) genotype 2. As RBV cannot be used in certain
situations, we examined whether PEG-IFN-alfa-2a monotherapy for 24 weeks or less would be sufficient to obtain a
sustained virological response (SVR) in patients infected with HCV genotype 2.
Methods: Forty-nine consecutive patients with HCV genotype 2 received PEG-IFN-alfa-2a (180 μg/week)
subcutaneously without oral RBV for 8-64 weeks. HCV RNA level was determined by COBAS AMPLICOR HCV Test,
v2.0.
Results: HCV RNA was equal to or less than 100 KIU/mL (defined as low viral load) in 15 of 49 patients, and the
remaining 34 had HCV RNA above 100 KIU/mL (defined as high viral load). All 15 patients with low viral load
achieved rapid virological response (RVR; HCV RNA negative at week 4), and also achieved SVR with an average
treatment duration of 17.1 weeks. The 34 patients with high viral load were treated for 33.7 weeks on average, and
19 of them (55.9%) achieved RVR. The SVR rates of these patients were significantly higher in those with RVR than
without RVR (16/19 vs. 6/15 p = 0.0074).
Conclusion: PEG-IFN-alfa-2a monotherapy for 24 weeks or less might be sufficient to treat selected patients with
HCV genotype 2, especially those with low viral load and becoming negative for HCV RNA by week 4 of treatment.
Background
Hepatitis C virus (HCV) is a major causative agent of
chronic hepatitis, hepatic cirrhosis and hepatocellular
carcinoma [1]. The number of cases of end-stage liver
diseases caused by chronic HCV infection and being
referred for liver transplantation is increasing rapidly
[2]. The current standard care for chronic hepatitis C is
based on the combination of pegylated-interferon (PEG-
IFN) and ribavirin (RBV) for 48 weeks, and this treat-
ment results in ~50% sustained virological response
(SVR) in patients with HCV genotype 1 and high viral
loads [3]. Among HCV genotypes other than HCV gen-
otype 1, HCV genotypes 2/3 patients in particular show
70-80% SVR by this treatment for 24 weeks [4-6].
Recent studies revealed that a shorter course of ther-
apy, for 12 weeks, with PEG-IFN-alfa-2b and RBV is as
effective as a 24-week course for patients with certain
HCV genotype 2/3 who show a rapid virological
response (RVR) to treatment at 4 weeks [6], although
treatment with PEG-IFN and RBV for 12 or 16 weeks in
patients infected with HCV genotype 2 or 3 results in a
lower overall SVR rate than treatment with the standard
24-week regimen [5,7].
On the other hand, PEG-IFN-alfa-2a without RBV
induces SVR in some transplant recipients with recur-
rent hepatitis C [8] or in some dialysis patients infected
with HCV [9]. In patients with cirrhosis, IFN, either
alone or in combination with ribavirin, has been used
cautiously, largely because it may exacerbate existing
neutropenia and thrombocytopenia [10]. In general,
PEG-IFN-alfa-2a monotherapy was better tolerated than
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monotherapy was associated with a ~20% rate of SVR in
patients infected with HCV genotype 1 [11].
Among pretreatment virological variables, the pre-
sence of HCV genotype 2 or 3 infection is the most
powerful predictor of SVR [12], as patients with HCV
genotype 2 are more likely to achieve SVR than those
with genotype 1. Further, patients with lower titers of
HCV RNA are also more likely to achieve SVR [13]. In
this study, we sought to determine whether PEG-IFN
monotherapy for fewer than 24 weeks would be effective
in patients with HCV genotype 2.
Methods
Patients
In this study, we analyzed 49 patients infected with
HCV genotype 2 at Chiba University Hospital between
January 2004 and December 2008. All patients fulfilled
the following criteria: 1) a history of abnormal liver
function for more than 24 weeks, 2) positivity for anti-
HCV antibody and HCV RNA, 3) HCV genotype 2, 4)
negativity for HBs antigen, 5) negativity for anti-HIV, 6)
no high titers of anti-nuclear antibodies, 7) no history of
alcohol abuse, 8) not taking immunosuppressive drugs,
and 9) liver biopsy findings compatible with chronic
viral hepatitis.
Patients received PEG-IFN-alfa-2a (180 μg/week) sub-
cutaneously without oral RBV for 8-64 weeks. The pos-
sible risks and benefits of shorter or longer treatment
with PEG-IFN were explained to the patients so as to
decide on a shorter (equal to or less than 24 weeks) or
longer (more than 24 weeks) treatment protocol. This
study was approved by the ethics committee of Chiba
University, Japan (permission number G19033), and
conformed to the Helsinki Declaration. Informed con-
sent was obtained from all patients before enrollment in
this study.
Determination of HCV RNA titer and HCV genotype
Serum HCV RNA titer was measured using an Amplicor
HCV monitor assay, version 2.0 (range: 0.5-850 KIU/
mL) (Roche, Tokyo, Japan) [14]. HCV RNA was also
examined qualitatively with the Amplicor HCV assay
(Roche). The detection limit of this qualitative assay is
50 IU/mL, corresponding to 1.7 Log IU/mL by COBAS
TaqMan PCR assay [15]. HCV genotype was determined
using the antibody serotyping method of Tsukiyama-
Kohara et al. [16,17]. In this serotyping assay, HCV ser-
otypes 1 and 2 correspond to genotypes 1a/1b and 2a/
2b, respectively, according to the classification of Sim-
monds et al. [18]. It was reported that in 84% patients,
genotypes determined by this serological genotyping
assay showed complete agreement with those deter-
mined by group-specific PCR, with none revealing a
group opposite to that of the HCV genotype, and also
that the detection rate of the serological genotyping
assay was even higher than that of the PCR assay [17].
HCV RNA titer and HCV genotype were determined
within 3 months prior to starting IFN treatment, and
HCV RNA was assayed qualitatively at 24 weeks after
the end of treatment.
Serum liver function tests and hematology tests
Serum aminotransferase concentrations, other liver
function tests and hematology tests were performed
according to standard methods every 1 to 3 months
before treatment, during treatment, and for at least 24
weeks after the end of treatment.
Histological examination
Liver biopsies were performed within 6 months prior to
the start of treatment in cases whose informed consent
was obtained. Staging of fibrosis and grading of activity
were based on the classification of Desmet et al. [19].
Assessment of efficacy
The endpoint of the study was achievement of SVR,
defined as seronegativity of HCV RNA throughout 24
weeks of post-treatment follow-up. RVR was defined as
s e r o n e g a t i v i t yo fH C VR N Aa t4w e e k so ft h e r a p y .
Patients who had undetectable HCV RNA within the
initial 12 weeks of treatment were considered to have
had complete early virological response (cEVR). End-of-
treatment virological respons e( E O T V R )w a sd e f i n e da s
seronegativity of HCV RNA at the end of treatment.
Relapse was defined as HCV RNA reappearance during
the follow-up period in patients who had achieved an
EOTVR [20].
Statistical analysis
Statistical analysis was carried out using Student’st - t e s t
or chi-square test, and p < 0.05 was considered statisti-
cally significant.
Results
Profile of the patients
Forty-nine patients infected with HCV genotype 2 were
enrolled. The HCV RNA level was 100 KIU/mL or
more (defined as high viral load) in 34 and less than
100 KIU/mL (defined as low viral load) in 15 patients.
Age, gender, ALT levels and platelet counts are shown
in Table 1. As for histological findings [19], there were
no significant differences between the high and low viral
load groups (N = 7 and N = 21, respectively). Fibrosis
staging of the high and low viral load groups was 1.5 ±
1.3 and 1.7 ± 0.9 (P = 0.65), and activity grading was 1.3
± 0.5 and 1.8 ± 0.6 (P = 0.058), respectively. Of 49
patients enrolled, 43 were treatment-naïve, 5 had a
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the 15 patients with low viral load, only one patient had
a history of IFN-alfa treatment. There were statistically
significant differences of RVR between low viral load
and high viral load groups (100% and 55.9%, respec-
tively), and the two-tailed P-value was 0.0059 by chi-
square test with Yates correction (Table 1).
Treatment response in HCV genotype 2-patients with low
viral load
The 15 patients with low viral load were treated for 17.1
± 11.4 weeks (range, 7-44 weeks), and all achieved RVR
as well as cEVR, EOTVR and SVR. None of them
stopped treatment because of side effects (Figure 1). Of
the 15 patients, 14 patients were treatment-naïve. The
other patient, who had undergone IFN monotherapy,
was retreated for 44 weeks and achieved SVR.
Treatment response in HCV genotype 2-patients with
high viral load
The 34 patients with high viral load were treated for
33.7 ± 16.4 weeks (range; 7-64 weeks). 22 (64.7%) had
SVR, 4 (11.7%) relapsed and 4 (11.7%) did not respond.
Five of them discontinued treatment at week 8, 11, 17,
22 and 25, respectively, due to abdominal pain, skin
eruption and lack of virological response, and all but
one failed to achieve SVR. RVR was achieved in 19
patients (55.9%), and SVR rates were significantly higher
in those achieving RVR than in those who did not (16/
19, 84.2%; 6/15, 40%, respectively; P = 0.0074) (Figures
2, 3). cEVR as well as EOTVR were achieved in 24
patients (70.6%), and SVR rates were significantly higher
in those achieving cEVR than in those who did not (22/
24, 91.7%; 0/10, 0%, respectively; P < 0.001).
Treatment response in HCV genotype 2-patients with
high viral load and RVR
Of the 19 patients with high viral load and RVR, SVR
rates were 7/10 (70%) and 9/9 (100%) in patients treated
for ≤24 weeks and > 24 weeks, respectively (P =0 . 0 7 3 ) .
Of the 19 patients, 17 were treatment-naïve. The other
2 patients had been treated with IFN monotherapy, and
one of them achieved SVR.
Treatment response in HCV genotype 2-patients with
high viral load without RVR
Of the 15 patients with high viral load and without
RVR, SVR rates were 0/5 (0%) in patients treated for
Table 1 Demographic data of patients according to HCV
RNA levels
Groups Low Viral
Load
High Viral
Load
P-value
N1 5 3 4
Age (years) 50.8 ± 14.5 53.3 ± 11.7 N.S.
Gender (male/female) 11/4 21/13 N.S.
ALT (IU/L) 71.5 ± 56.5 100 ± 76.3 N.S.
Platelets (× 10
4/mm
3) 17.4 ± 5.5 100 ± 76.3 N.S.
HCV RNA (KIU/mL) 37.5 ± 26.3 459 ± 330 <
0.0001
Duration of treatment
(days)
120 ± 80 236 ± 115 N.S.
RVR/non-RVR 15/0 19/15 0.0059
Low and high viral load were defined as < 100 KIU/mL and > 100 KIU/mL,
respectively. ALT, alanine aminotransferase; RVR, rapid virological response; N.
S., statistically not significant. Data are shown as mean ± S.D. Statistical
analysis was carried out using Student’s t-test or chi-square test. P < 0.05 was
considered statistically significant.
Figure 1 Relationships between HCV viral loads and treatment
duration in 31 patients with RVR and SVR. 15 patients with low
viral load and 16 patients with high viral load are shown as black
and white diamonds, respectively.
Figure 2 Efficacy of IFN treatment in 19 patients with high
viral load who were HCV RNA seronegative at week 4
according to HCV RNA load and duration of treatment. Three
cases had 850 KIU/mL and treated for 11 months. Black triangles,
sustained virological response (SVR); white triangles, non-SVR.
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weeks (P = 0.025) (Figure 4). Of the 15 patients, 12
patients were treatment-naïve. Two of the other patients
had been treated with IFN monotherapy (one was
unknown), and these 2 patients achieved SVR.
Discussion
The present study showed that Japanese patients with
HCV genotype 2 and undetectable HCV-RNA at week 4
of treatment achieved a high SVR rate with PEG-IFN
monotherapy for 24 weeks or less. In Japan, between
December 2003 and March 2007, until the national
health insurance system approved the combination ther-
apy PEG-IFN-alfa-2a with RBV, PEG-IFN-alfa-2a mono-
therapy was used at 180 μg once a week for 24-48
weeks for the treatment of chronic hepatitis C. Even
now, we cannot use the combination therapy for HCV
genotype 2 treatment-naïve patients with low viral loads
under the national health insurance system in our coun-
try. Then, we used 180 μg of PEG-IFN-alfa-2a mono-
therapies for chronic hepatitis C patients and
retrospectively analyzed the data during this period in
the present study. This study was not a controlled trial,
and various durations of treatment were adopted for the
respective patients. However, the SVR rate of 100% in
patients with low viral load and 17.1 weeks as average
treatment duration and that of 84.2% in those with high
viral load and undetectable HCV-RNA at week 4 of
average treatment duration of 24 weeks were very high.
Therefore, 24 weeks of PEG-IFN therapy could repre-
sent a sufficient treatment duration for selected patients
with HCV genotype 2 and undetectable HCV-RNA at
week 4 of treatment.
Since IFN treatment, including PEG-IFN, can cause
medical conditions such as depression, interstitial pneu-
monia, diabetes mellitus, thyroid disease, leukopenia,
thrombocytopenia and flu-like symptoms, its duration
should preferably be minimal [21]. Therefore, to mini-
mize the possibility of such side effects, and additionally,
in consideration of the cost of IFN treatment, reducing
the length of treatment is desirable [22,23]. The combi-
nation therapy with PEG-IFN and RBV for 24 weeks has
been shown to be more effective, and it has become the
present standard care [11]. However, in some cases, and
especially in older patients, RBV cannot be administered
because of possible side effects, including severe anemia.
As patients tend to be older in Japan than in Western
countries, more therapeutic options are needed.
Recently, there have been several reports about the
importance of interleukin-28B (IL28B) SNP in the pre-
diction of SVR in HCV genotype 2-patients treated with
PEG-IFN-alfa plus RBV therapy [20,24-28]. IL28B SNP
rs8099917 was determined in 11 HCV genotype 2-
patients treated with IFN monotherapy, revealing that 5
and 6, respectively, had major (TT) and minor (TG and
GG) phenotypes and that 2 null-responders had TG
phenotypes, and 4 had relapsed and 5 had SVR [[29],
data not shown]. It is possible that IL28B SNP could
i m p r o v et h eS V Rr a t ei nn o n - R V Rp a t i e n t sa n dn o n -
responder patients by changing monotherapy to combi-
nation therapy [30], but further studies will be needed.
Recently, there have been reports that in HCV geno-
type 2/3-infected patients with a very rapid viral
response (vRVR), i.e. HCV RNA below 1,000 IU/mL on
day 7, the combination PEG-IFN plus RBV treatment
could be shortened to 12-16 weeks if no dose reduction
had been made [31]. Further studies will be needed to
reveal how long patients obtaining RVR should be trea-
ted. Our study indicates that PEG-IFN monotherapy for
24 weeks or less is sufficient to treat patients with HCV
Figure 3 Efficacy of IFN treatment of 15 patients with high
viral load who were HCV RNA seropositive at week 4
according to HCV RNA load and duration of treatment. Black
triangles, sustained virological response (SVR); white triangles, non-
SVR.
Figure 4 Summary of this study.
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HCV RNA by week 4 of treatment. On the other hand,
RBV combination therapy should be considered in those
whose HCV RNA becomes seropositive by week 4 of
treatment. Our results need to be confirmed by a rando-
mized control study as soon as possible. Our previous
studies showed that the overall SVR rate of HCV geno-
type 2-patients treated with PEG-IFN-alfa-2b plus RBV
for 16-48 weeks was 82.6% [30], and the SVR rate of
combination treatments for some patients infected with
HCV genotype 2 was superior to that of PEG-IFN-alfa-
2a monotherapy (75.5%) in the present study. Although
our retrospective study had a rather small sample size
with various treatment durations, our results may pro-
vide support to the future design of personalized therapy
for HCV genotype 2-patients in certain situations where
they cannot be treated with RBV.
Conclusion
PEG-IFN-alfa-2a monotherapy for 24 weeks or less
might be sufficient to treat selected patients with HCV
genotype 2, especially those with low viral load and
becoming negative for HCV RNA by week 4 of treat-
m e n t .I fw ec o u l du s eI L 2 8 BS N Pa n dv R V Rf o rs e l e c t -
ing patients, PEG-IFN-alfa-2a monotherapy would be
sufficient to allow some HCV genotype 2-patients to
clear HCV.
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